scholarly journals Colchicine for Acute Gout

2021 ◽  
Author(s):  
Michael Gottlieb ◽  
Willeed Rabah ◽  
Brit Long
Keyword(s):  
Acute Gout

Acute gout secondary to psoriasis exacerbated by photochemotherapy

1982 ◽  
Vol 118 (3) ◽  
pp. 211-211 ◽  
Author(s):  
J. W. Burnett
Keyword(s):  
Acute Gout

Colchicine for acute gout

2021 ◽  
Vol 2021 (8) ◽  
Author(s):  
Bayden J McKenzie ◽  
Mihir D Wechalekar ◽  
Renea V Johnston ◽  
Naomi Schlesinger ◽  
Rachelle Buchbinder
Keyword(s):  
Acute Gout

Sesquiterpene lactones from Lychnophora species: Antinociceptive, anti-inflammatory, and antioxidant pathways to treat acute gout

2021 ◽  
Vol 269 ◽  
pp. 113738
Author(s):  
Ana Catharina Fernandes Pereira Ferreira Bernardes ◽  
Rafaela Cunha Matosinhos ◽  
Marcela Carolina de Paula Michel Araújo ◽  
Camila Helena Barros ◽  
Rodrigo Dian de Oliveira Aguiar Soares ◽  
...  
Keyword(s):  
Sesquiterpene Lactones ◽  
Acute Gout ◽  
Anti Inflammatory

Medical Management of Acute Gout

2012 ◽  
Vol 37 (10) ◽  
pp. 2160-2164
Author(s):  
Peter C. Chimenti ◽  
Warren C. Hammert
Keyword(s):  
Medical Management ◽  
Acute Gout

Effectiveness of Anakinra in Acute Gout

2017 ◽  
Vol 24 (5) ◽  
pp. e633-e634 ◽  
Author(s):  
Sarah E. Petite
Keyword(s):  
Acute Gout

Acute Gout During Chlorothiazide Therapy

1960 ◽  
Vol 53 (6) ◽  
pp. 736-738 ◽  
Author(s):  
ROBERT RAY McGEE
Keyword(s):  
Acute Gout

scholarly journals Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study

BMJ Open ◽  
2017 ◽  
Vol 7 (9) ◽  
pp. e017121 ◽  
Author(s):  
Gowrie Balasubramaniam ◽  
Trisha Parker ◽  
David Turner ◽  
Mike Parker ◽  
Jonathan Scales ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Controlled Trial ◽  
Interleukin 1 ◽  
Scale Up ◽  
General Information ◽  
Primary Objective ◽  
Retention Rates ◽  
Acute Gout ◽  
Double Blind

IntroductionAcute gout occurs in people with chronic kidney disease, who are commonly older people with comorbidities such as hypertension, heart disease and diabetes. Potentially harmful treatments are administered to these vulnerable patients due to a lack of clear evidence. Newly available treatment that targets a key inflammatory pathway in acute gout attacks provides an opportunity to undertake the first-ever trial specifically looking treating people with kidney disease. This paper describes the protocol for a feasibility randomised controlled trial (RCT) comparing anakinra, a novel interleukin-1 antagonist versus steroids in people with chronic kidney disease (ASGARD).Methods and analysisASGARD is a two-parallel group double-blind, double-dummy multicentre RCT comparing anakinra 100 mg, an interleukin-1 antagonist, subcutaneous for 5 days against intramuscular methylprednisolone 120 mg. The primary objective is to assess the feasibility of the trial design and procedures for a definitive RCT. The specific aims are: (1) test recruitment and retention rates and willingness to be randomised; (2) test eligibility criteria; (3) collect and analyse outcome data to inform sample and power calculations for a trial of efficacy; (4) collect economic data to inform a future economic evaluation estimating costs of treatment and (5) assess capacity of the project to scale up to a national multicentre trial. We will also gather qualitative insights from participants. It aims to recruit 32 patients with a 1:1 randomisation. Information from this feasibility study will help design a definitive trial and provide general information in designing acute gout studies.Ethics and disseminationThe London-Central Ethics Committee approved the protocol. The results will be disseminated in peer-reviewed journals and at scientific conferences.Trial registration numberEudraCT No. 2015-001787-19, NCT/Clinicalstrials.gov No.NCT02578394, pre-results, WHO Universal Trials Reference No. U1111-1175-1977. NIHR Grant PB-PG-0614–34090.

Sign in / Sign up

Export Citation Format

Share Document